15.65
0.06 (0.38%)
| Previous Close | 15.59 |
| Open | 15.55 |
| Volume | 713,794 |
| Avg. Volume (3M) | 439,579 |
| Market Cap | 5,579,793,920 |
| Price / Earnings (Forward) | 14.39 |
| Price / Sales | 1.07 |
| Price / Book | 0.880 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2026 |
| Profit Margin | -7.50% |
| Operating Margin (TTM) | -5.36% |
| Diluted EPS (TTM) | -1.02 |
| Quarterly Revenue Growth (YOY) | 3.50% |
| Total Debt/Equity (MRQ) | 75.07% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 166.00 M |
| Levered Free Cash Flow (TTM) | 69.00 M |
| Return on Assets (TTM) | 0.61% |
| Return on Equity (TTM) | -5.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Bullish | Mixed | |
| Stock | Bausch + Lomb Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -3.5 |
| Average | -0.40 |
|
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 88.13% |
| % Held by Institutions | 10.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Silver Point Capital L.P. | 31 Mar 2026 | 2,245,000 |
| Whitebox Advisors Llc | 31 Mar 2026 | 1,101,854 |
| Clark Estates Inc/Ny | 31 Mar 2026 | 825,000 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ALFONSO EDUARDO | 15.78 | - | 15,842 | 249,987 |
| BERNIER NATHALIE D. | 15.78 | - | 15,842 | 249,987 |
| COLLIS STEVEN H | 15.78 | - | 15,842 | 249,987 |
| KAVANAGH SARAH B | 15.78 | - | 15,842 | 249,987 |
| LING KAREN | 15.78 | - | 15,842 | 249,987 |
| PAULSON JOHN | 15.78 | - | 15,842 | 249,987 |
| ROBERTSON RUSSEL C | 15.78 | - | 15,842 | 249,987 |
| ROSS THOMAS W. SR. | 15.78 | - | 15,842 | 249,987 |
| SAUNDERS BRENT L | - | 15.92 | -2,886 | -45,945 |
| VON ESCHENBACH ANDREW C. | 15.78 | - | 15,842 | 249,987 |
| Aggregate Net Quantity | 139,692 | |||
| Aggregate Net Value ($) | 2,203,936 | |||
| Aggregate Avg. Buy ($) | 15.78 | |||
| Aggregate Avg. Sell ($) | 15.92 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ALFONSO EDUARDO | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| BERNIER NATHALIE D. | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| COLLIS STEVEN H | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| KAVANAGH SARAH B | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| LING KAREN | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| PAULSON JOHN | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| ROBERTSON RUSSEL C | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| ROSS THOMAS W. SR. | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| VON ESCHENBACH ANDREW C. | Director | 26 May 2026 | Acquired (+) | 15,842 | 15.78 | 249,987 |
| SAUNDERS BRENT L | Officer | 22 May 2026 | Disposed (-) | 2,886 | 15.92 | 45,945 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |